Press releaseGlobe Newswire
Sonnet Biotherapeutics Holdings
SONN · NASDAQ
$51.02+$51.02 (+0.00%)TodayMarket closed ·
Prev close $0.00
Latest news
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- Press releaseGlobe Newswire
Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HBI, BFIN, PBBK, SONN on Behalf of Shareholders
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseGlobe Newswire
Sonnet Releases Virtual Investor "What This Means" Segment
- Press releaseGlobe Newswire
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- Press releaseGlobe Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SONN, FCCO, MGRM on Behalf of Shareholders
- Press releasePRNewswire
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: SONN, SKX, FCCO, and SGBG
- NewsShivdeep Dhaliwal
Palantir, The Trade Desk, Tilray, Sonnet Biotherapeutics, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
- Press releaseGlobe Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRNA, KLG, MRGM, SONN on Behalf of Shareholders
- NewsAvi Kapoor
Crude Oil Moves Lower; Daré Bioscience Shares Jump
- NewsVandana Singh
Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?
- NewsAvi Kapoor
US Stocks Edge Lower; Fastenal Posts Upbeat Earnings
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGRM, WAT, SONN on Behalf of Shareholders
- Press releaseBusiness Wire
SONN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sonnet BioTherapeutics, Inc. Is Fair to Shareholders
- News
Market-Moving News for July 14th
- Press releaseGlobe Newswire
Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy
- NewsRishabh Mishra
US Stocks Likely To Open Lower After A Week Of Records: Tesla In Focus As Elon Musk Announces America Party
- NewsMohd Haider
Sonnet BioTherapeutics Drops 5% Intraday, Rebounds 14% After Hours Amid Delisting Concerns
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- NewsAvi Kapoor
Dow Jumps Over 200 Points; US Nonfarm Payrolls Beat Estimates
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseGlobe Newswire
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit
- Press releaseGlobe Newswire
Sonnet Releases Virtual Investor "What This Means" Segment
- Press releaseGlobe Newswire
Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
- Press releaseGlobe Newswire
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
- NewsAvi Kapoor
Gold Down Over 2%; CVS Health Shares Jump After Q3 Results
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Dow Jumps Over 1,200 Points; Donald Trump Wins White House
- NewsAvi Kapoor
Dow Jumps Over 300 Points; ON Semiconductor Earnings Top Views
- Press releaseGlobe Newswire
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
- NewsAvi Kapoor
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket
- NewsHenry Khederian
Why Sonnet BioTherapeutics (SONN) Shares Are Down 19% Today
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.